Tirzepatide study investigates long-term weight loss maintenance in participants with obesity or overweight.

Obesity and overweight are chronic conditions associated with numerous comorbidities, including type 2 diabetes, cardiovascular disease, and certain cancers. While various interventions can induce initial weight loss, maintaining this loss long-term remains a significant challenge, often due to physiological adaptations that promote weight regain. Current standard-of-care approaches, including lifestyle modifications and existing pharmacotherapies, frequently fall short in providing sustained efficacy. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated substantial efficacy in initial weight reduction. This study aims to address the critical gap in understanding its role in long-term weight loss maintenance.

This 2-year (25 visits) study enrolled participants with obesity or overweight to assess tirzepatide's ability to maintain weight loss. The trial comprised two phases: an initial lead-in phase where all participants received tirzepatide, followed by a treatment phase. In the treatment phase, participants were randomized to either continue tirzepatide or switch to a placebo. Dosing involved a once-weekly subcutaneous (QW SC) administration, starting at 2.5 mg and escalating by 2.5 mg every 4 weeks up to a maximum of 15 mg for the primary treatment period (Week 0-Week 72). The primary endpoint focused on the maintenance of body weight loss.

This record describes the design and protocol of a clinical trial investigating tirzepatide for weight loss maintenance. As of this publication, specific results, including efficacy data, statistical analyses, or adverse event rates, are not yet available from the provided abstract. The study is designed to gather comprehensive data on the long-term effects of tirzepatide in sustaining weight reduction.